NORTH BRISTOL NHS TRUST

Serac Healthcare and the University of Exeter announce the first patient scan using ^99mTc-maraciclatide in the PREDICT-ILD Phase II study, aiming to evaluate its efficacy as an imaging marker for ILD prognostication. The study, led by Professors Chris Scotton and Giles Dixon, is funded by the Wellcome Trust and involves 69 participants, with 15 in the sub-study. The primary endpoint is to compare ^99mTc-maraciclatide uptake between IPF, non-IPF fibrosing-ILD, and healthy controls.

Serac Healthcare and University of Exeter start Phase II study on 99mTc-maraciclatide, a SPECT imaging agent for ILD prognostication. PREDICT-ILD aims to assess CT effectiveness in ILD progression detection, with a sub-study evaluating 99mTc-maraciclatide. Recruitment ongoing at three NHS sites, led by Professors Scotton and Dixon, funded by Wellcome Trust. Sub-study to compare 99mTc-maraciclatide uptake between IPF, non-IPF fibrosing-ILD, and healthy controls, aiming to predict disease progression.